188116-07-6

Basic information

• Product Name: 1-(4-chlorophenyl)-4-morpholin-4-yl-5H-imidazol-2-one
• Synonyms: 1-(4-chlorophenyl)-4-morpholin-4-yl-5H-imidazol-2-one;Imepitoin;1-(4-Chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one;2H-Imidazol-2-one,1-(4-chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-;Imepitoin 1-(4-Chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one;AWD 131-138, >=98%;3-(4-chlorophenyl)-5-morpholin-4-yl-4H-imidazol-2-one
• CAS NO: 188116-07-6
• Molecular Formula: C₁₃H₁₄ClN₃O₂
• Molecular Weight: 279.72
• EINECS: 200-256-5
• Product Categories: Inhibitors
• Mol File: 188116-07-6.mol

Chemical Properties

• Melting Point: 264℃ (ethanol )
• Boiling Point: 421.8°Cat760mmHg
• Flash Point: 208.9°C
• Appearance: /
• Density: 1.42g/cm³
• Vapor Pressure: 2.53E-07mmHg at 25°C
• Refractive Index: 1.664
• Storage Temp.: 2-8°C
• PKA: 4.39±0.20(Predicted)
• CAS DataBase Reference: 1-(4-chlorophenyl)-4-morpholin-4-yl-5H-imidazol-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-chlorophenyl)-4-morpholin-4-yl-5H-imidazol-2-one(188116-07-6)
• EPA Substance Registry System: 1-(4-chlorophenyl)-4-morpholin-4-yl-5H-imidazol-2-one(188116-07-6)

Safety Data

• Hazardous Substances Data: 188116-07-6(Hazardous Substances Data)

Usage

Uses

As the specific applications and uses of 1-(4-chlorophenyl)-4-yl-5H-imidazol-2-one have not been widely studied or reported, it is not possible to provide a detailed list of its applications at this time. However, given the presence of an imidazole ring and a morpholine structure, it can be hypothesized that 1-(4-chlorophenyl)-4-morpholin-4-yl-5H-imidazol-2-one may have potential applications in the pharmaceutical industry, similar to other compounds with these structures. Further research and experimentation would be required to confirm its suitability and effectiveness in any specific application.

InChI:InChI=1/C13H14ClN3O2/c14-10-1-3-11(4-2-10)17-9-12(15-13(17)18)16-5-7-19-8-6-16/h1-4H,5-9H2

Upstream product

• 32549-33-0 1-(4-chlorophenyl)imidazolidine-2,4-dione 
• 10024-89-2 morpholin hydrochloride 

Relevant articles and documents

Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors

New series of imidazolones and pyrrolones were synthesized. The compounds were tested regarding their anxiolytic properties due to modulation of the GABAA receptor response. Several derivatives exhibit considerable pharmacological activity while lacking the typical side effects of benzodiazepine receptor agonists. 1-(4-chlorophenyl)-4-morpholin-1-yl-1,5- dihydro-imidazol-2-one (2) and 1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro- imidazol-2-one (3) were protective in the pentylenetetrazole test in rats with oral ED50 of 27.4 and 12.8 mg/kg and TD50 (rotarod) of >500 and 265 mg/kg, respectively. The minimum effective dose in the Vogel conflict test was 3 mg/kg for both compounds. Common structure-activity relationship and comparative molecular field analysis models of the various series of derivatives could be established which are in accordance with a GABAA mediated pharmacological action. The findings fit well into an established pharmacophore model. This model is refined by an additional steric restriction feature.

Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making

Compounds having anticonsulive activity, of the formula 1 STR1 in which X is hydrogen, a C1-4 -alkyl, C1-4 alkoxy, trifluoromethyl, or halogen residue, R1 and R2 are independently of each other C1-4 -alkyl, C2-4 hydroxyalkyl, cycloalkyl or heteroalkyl, or R1 and R2 are together a C2-6 alkylene reside in which a--CH2 --group is optionally replaced by oxygen, nitrogen or sulfur, m is 0 or 1, and n is 0 or a cardinal number from 1 to 5, and their pharmaceutically acceptable salts. The application also relates to a process for making the compound of formula (I).

For a process for treatment of anxiety and tension

A process for the treatment of anxiety and tension, which comprises administering to a patient in need therefor an anxiolytically effective amount of a compound of the formula STR1 wherein X is hydrogen, a C1-4 alkyl, C1-4 alkoxy, trifluoromethyl residue, or halogen; R1 and R2 are independently of each other a C1-4 alkyl, cycloalkyl, C2-4 hydroxyalkyl, or heteroalkyl residue, or R1 and R2 together form a C2-6 alkylene residue in which one --CH2 -- group can be replaced by oxygen, nitrogen or sulfur; n is 0 or 1, and m is 0 or a cardinal number from 1-5, or a pharmaceutically acceptable salt of the compound.